VIR
Vir Biotechnology, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
9.78
▲ 0.57 (6.19%)
MARKET · —
Price
Open
9.22
Prev close
9.21
Day high
9.86
Day low
9.31
Volume
1.73M
Market cap
$1.65B
P/E (TTM)
—
52W range
4.35 – 11.66
Trailing performance
Returnvs SPY
1W
+5.84%
+7.2%
1M
+4.71%
+1.0%
3M
+8.31%
+5.2%
6M
+29.37%
+18.3%
YTD
+62.19%
+49.9%
1Y
+124.31%
+104.3%
3Y
-23.95%
-98.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$1.65B
Enterprise value$1.22B
Revenue (TTM)$303.23M
Gross profit$-180.08M
EBITDA$-267.96M
Net income$-251.68M
EPS (TTM)$-1.77
Free cash flow$-38.89M
Total cash$532.73M
Total debt$93.27M
Book value / share$5.04
Shares outstanding169.22M
Float129.79M
Short % of float11.39%
Dividend yield—
Beta (5Y)1.59
Valuation & profitability ratios
Trailing P/E—
Forward P/E-3.92
PEG ratio—
Price / sales—
Price / book1.94
EV / revenue4.01
EV / EBITDA-4.54
Gross margin-59.39%
Operating margin30.75%
Profit margin-83.00%
Return on equity-26.08%
Return on assets-14.51%
Debt / equity9.49
Current ratio6.04
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $68.56M | $74.20M | $86.18M | $1.62B |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$437.99M | -$521.96M | -$615.06M | $515.84M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$437.99M | -$521.96M | -$615.06M | $515.84M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.90 | 0.47 | -47.5% |
| Mar 2026 | 0.48 | -0.85 | -276.6% |
| Dec 2025 | -0.45 | -0.31 | +31.6% |
| Sep 2025 | -0.86 | -1.17 | -36.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.75 | 8 | $865.12K | +260.5% |
| Next quarter | -0.65 | 8 | $6.30M | -90.2% |
| Current year | -1.78 | 8 | $245.35M | +257.9% |
| Next year | -2.49 | 8 | $93.99M | -61.7% |
Analyst targets & ownership
Mean target$21.00
High target$30.00
Low target$15.00
Implied upside114.72%
Analyst count9
ConsensusSTRONG BUY
Strong buy / Buy3 / 7
Hold0
Sell / Strong sell0 / 0
Held by insiders6.57%
Held by institutions84.26%
Institutions holding336
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+321.51K
Net buying
Buy transactions
13
581.38K shares
Sell transactions
18
259.87K shares
Net transactions
+31
Buys less sells
Sell : buy shares
0.4 : 1
Mixed
Insider-held shares
11.11M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 9, 26 | COUGHLIN TIMOTHY Director |
STOCK | 16.00K | $0 | Direct |
| Jun 1, 26 | NAPOLITANO JANET ANN Director |
SELL | 3.20K | $30.24K | Direct |
| Jun 1, 26 | SABATINI BRENT Officer |
SELL | 379 | $3.58K | Direct |
| May 27, 26 | SIGAL CHARLES ELLIOTT Director |
STOCK | 8.00K | $0 | Direct |
| May 27, 26 | BISCHOFBERGER NORBERT W Director |
STOCK | 8.00K | $0 | Direct |
| May 27, 26 | MORE ROBERT J Director |
STOCK | 8.00K | $0 | Direct |
| May 27, 26 | HATFIELD JEFFREY S Director |
STOCK | 8.00K | $0 | Direct |
| May 27, 26 | RAMY SAMIR FARID PH.D. Director |
STOCK | 8.00K | $0 | Direct |
| May 27, 26 | NAPOLITANO JANET ANN Director |
STOCK | 8.00K | $0 | Direct |
| May 1, 26 | SATO VICKI LEE Director |
SELL | 22.00K | $221.03K | Direct |
| Apr 6, 26 | DE BACKER MARIANNE Chief Executive Officer |
SELL | 72.56K | $664.35K | Direct |
| Apr 1, 26 | SATO VICKI LEE Director |
SELL | 22.00K | $199.62K | Direct |
| Mar 23, 26 | SABATINI BRENT Officer |
SELL | 7.71K | $70.32K | Direct |
| Mar 2, 26 | SATO VICKI LEE Director |
SELL | 22.00K | $209.18K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
DE BACKER MARIANNE |
Chief Executive Officer | 1.00M | Sale |
DE VERNEUIL VANINA ALEXANDRA HUARD |
General Counsel | 112.98K | Sale |
EISNER MARK E |
Officer | 154.02K | Sale |
HANLY ANN M |
Chief Technology Officer | 117.90K | Sale |
MORE ROBERT J |
Director | 558.57K | Stock Award(Grant) |
O'BYRNE JASON |
Chief Financial Officer | 162.62K | Sale |
SABATINI BRENT |
Officer | 61.90K | Sale |
SATO VICKI LEE |
Director | 1.08M | Sale |
SCANGOS GEORGE A |
Director | 3.81M | Sale |
SVF ENDURANCE CAYMAN LTD |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
Moving averages & technicals
SMA 10
9.27
+5.55% from price
SMA 20
9.06
+7.90% from price
SMA 50
9.37
+4.37% from price
SMA 100
9.44
+3.56% from price
SMA 200
8.30
+17.79% from price
EMA 12
9.31
+5.02% from price
EMA 26
9.25
+5.73% from price
EMA 50
9.27
+5.48% from price
RSI (14)
59.0
Neutral
MACD (12,26,9)
0.06
Hist 0.10
ATR (14)
0.44
4.50% of price
Realised vol 30D
43.6%
Annualised
Bollinger upper
9.71
20, 2σ
Bollinger lower
8.42
20, 2σ
50 / 200 cross
Golden
9.37 vs 8.30
Trend bias
Above 200
+17.79%
Risk profile
Beta vs SPY
1.77
More volatile than market
Correlation to SPY
0.34
Loosely linked
Realised vol 30D
43.6%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-25.6%
Peak to trough
Max drawdown 5Y
-92.2%
Peak to trough
ATR 14
0.44
4.50% of price
Beta (reported)
1.59
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.05
Call-heavy session
Put / call open interest
1.13
Positioning, not flow
Max pain
9.00
-8.0% from spot
ATM implied vol
50.6%
Nearest strike to spot
Skew (10% OTM)
+5.9%
Puts bid over calls
Call volume
175
Contracts, this expiry
Put volume
8
Contracts, this expiry
Heaviest call OI
9.00
510 contracts
Heaviest put OI
9.00
568 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Olema Pharmaceuticals Names Jason O'Byrne CFO
MT Newswires · 9d ago
Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript
Motley Fool · 10d ago
Vir Biotechnology, Inc. Q2 2026 Earnings Call Summary
Moby · 16d ago
Vir Biotechnology Q2 Earnings Call Highlights
MarketBeat · 16d ago
Vir Biotechnology Inc (VIR) (Q2 2026) Earnings Call Highlights: 88% HDV Cure Rate and a $1B ...
GuruFocus.com · 17d ago
Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates
Zacks · 17d ago
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Business Wire · 17d ago
Earnings To Watch: Vir Biotechnology Inc (VIR) Q2 2026 -- GF Value Sees 175% Upside
GuruFocus.com · 18d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.